Clinical Trials Logo

Filter by:
NCT ID: NCT05662488 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy

Start date: September 1, 2020
Phase:
Study type: Observational

The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with anti-PD-1 antibodies-based combination therapy.

NCT ID: NCT05662020 Active, not recruiting - Clinical trials for Human Papillomavirus Infection

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Start date: March 23, 2022
Phase: Phase 3
Study type: Interventional

The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune response induced with same conditions in 9-19 age group is non-inferior to 20-26 age group, and if the immune response induced by 9-valent HPV study vaccine administrated with 2-dose schedule in females aged 9-14 years is non-inferior to 3-dose schedule in females aged 20-26 years.

NCT ID: NCT05661357 Active, not recruiting - Colorectal Cancer Clinical Trials

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

HCCSC-C03
Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures

NCT ID: NCT05660720 Active, not recruiting - Healthy Subject Clinical Trials

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Start date: November 19, 2022
Phase: Phase 1
Study type: Interventional

This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

NCT ID: NCT05659927 Active, not recruiting - Asthma Clinical Trials

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Start date: February 9, 2023
Phase: Phase 1
Study type: Interventional

To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects

NCT ID: NCT05659043 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Glycation of apoA-I and Diabetic Atherogenesis

Start date: January 2017
Phase:
Study type: Observational

The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis. ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the development of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, by consecutively enrolling diabetic patients with (two to three hundred) or without CAD (controls, six to eight hundred) in our hospital, we will isolate their serum HDL and perform a qualitative and quantitative proteomic analysis of apoA-I glycation. The relation of apoA-I glycation and HDL function and angiography-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients to analyze the influence of apoA-I glycation on the outcome including plaque progression.

NCT ID: NCT05658718 Active, not recruiting - Refractive Surgery Clinical Trials

Factors Influencing Nocturnal Symptoms After Refractive Surgery.

Start date: November 1, 2021
Phase:
Study type: Observational

By comparing the parameters of the two groups of patients with glare at night after refractive surgery and those without glare at night, the influence of preoperative related parameters on postoperative glare was analyzed.

NCT ID: NCT05658484 Active, not recruiting - Multiple Sclerosis Clinical Trials

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Start date: June 9, 2023
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.

NCT ID: NCT05658003 Active, not recruiting - Clinical trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of [177Lu]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic castration-resistant prostate cancer patients, who were previously treated with another ARDT as last treatment and who have not been exposed to a taxane-containing regimen in castrate resistant prostate cancer (CRPC) or hormone-sensitive prostate cancer (HSPC) settings and who are considered appropriate for delaying taxane-based chemotherapy. The primary endpoint of rPFS will be assessed via blinded independent centralized review of radiographic images provided by the treating physician and as outlined in Prostate Cancer Working Group 3 (PCWG3) guidelines.

NCT ID: NCT05657951 Active, not recruiting - Clinical trials for Zonule of Zinn Abnormality

Repeatability and Reproducibility of Lens Zonule Length Measurement Using ArcScan Insight 100

Start date: August 1, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the intra-examiner repeatability and inter-examiner reproducibility in lens zonule length measurements using very high-frequency (VHF) digital ultrasound (ArcScan Insight 100).